Are People With Myasthenia Gravis Immunocompromised? What Depends on the Condition and Its Treatment

TL;DR

• Myasthenia gravis (MG) is an autoimmune condition, but having MG does not automatically mean you are immunocompromised.
• Some MG treatments suppress or modify the immune system, which can increase susceptibility to certain infections.
• Infection risk depends on the type of treatment, treatment intensity, duration, combinations and individual health factors.
• Some newer MG treatments affect specific parts of the immune system rather than broadly suppressing immune activity.
• Experiences shared through mama health show that infection risk can also affect everyday decisions around social contact, vaccination and communication with healthcare professionals.

Are people with myasthenia gravis immunocompromised?

Not necessarily. Myasthenia gravis is an autoimmune condition, but autoimmunity is not the same as having a weakened immune system.

In MG, the immune system mistakenly interferes with communication between nerves and muscles. This happens when antibodies target proteins involved in signalling at the neuromuscular junction, where nerves communicate with muscles. [1,2]

The immune system in MG is therefore misdirected rather than simply weak.

For many people living with MG, whether they are considered immunocompromised depends more on their treatment than on MG itself.

Some treatments mainly improve nerve-to-muscle communication and do not broadly suppress immune activity. Other treatments reduce or modify the immune response to limit the autoimmune processes involved in MG.

This means two people with MG may have very different levels and types of infection risk.

For more background on the autoimmune process, read mama health’s guide to how antibodies are involved in myasthenia gravis.

Is an autoimmune condition the same as being immunocompromised?

No. Autoimmunity and immunocompromise describe different changes in how the immune system works.

Autoimmunity means the immune system reacts against the body's own cells, tissues or biological processes.

Being immunocompromised means that part of the body's normal ability to defend itself against infection has been reduced.

Someone can therefore have an autoimmune condition without having broadly weakened immune defences.

This distinction is especially important in MG because treatments work in different ways.

Someone whose treatment focuses on improving nerve-to-muscle signalling may have a different infection-risk profile from someone receiving long-term immune-suppressing or immune-targeting treatment.

To understand why MG affects muscle strength, see mama health’s guide to receptors and the neuromuscular junction in MG.

Which MG treatments can affect the immune system?

Some MG treatments reduce immune activity broadly, while others target specific parts of the immune system.

Treatment approaches for MG can affect immunity in several different ways.

Do symptom-focused MG treatments suppress the immune system?

Some symptom-focused treatments do not suppress the immune system.

These treatments work by improving communication between nerves and muscles rather than changing the autoimmune response itself.

If someone uses only this type of treatment, the treatment itself does not make them immunocompromised.

Other health conditions and individual factors can still affect infection risk.

How do broad immune-suppressing treatments affect immunity?

Broad immune-suppressing treatments reduce immune activity and can make it harder for the body to respond to some infections.

These treatments are used to reduce the abnormal immune response involved in MG.

The degree of immune suppression is not the same for everyone.

It can depend on factors such as:

• treatment intensity;
• how long treatment has been used;
• whether more than one immune-suppressing treatment is used;
• age;
• other health conditions;
• previous infections;
• individual immune function.

For this reason, being described as “immunocompromised” does not identify one fixed level of risk.

How do B-cell-targeting treatments affect immunity?

Treatments that target B cells can affect antibody-related immune defences and infection risk.

B cells are an important part of the immune system. They are involved in producing antibodies that help the body recognise and respond to infections.

Some MG treatments reduce B-cell activity or B-cell numbers to limit the autoimmune response.

Because B cells also contribute to normal immune protection, these treatments can influence infection risk and the body's response to some vaccines. [2,3]

Their immune effects may also continue for a period after treatment has been given.

How do complement-targeting treatments affect immunity?

Complement-targeting treatments affect a specific immune defence pathway and can create particular infection risks.

The complement system is part of the immune system. It is involved in the autoimmune processes that damage nerve-to-muscle communication in some forms of MG.

However, the complement system also helps protect the body against certain bacterial infections.

Blocking this pathway can therefore increase susceptibility to specific infections. Vaccination and other preventive measures may be required around this type of treatment. [3,4]

This is different from broadly suppressing the entire immune system.

How do treatments that lower circulating antibodies affect immunity?

Some newer MG treatments lower certain circulating antibodies, including antibodies involved in MG.

These approaches interfere with the biological process that normally keeps certain antibodies circulating in the bloodstream.

Reducing these antibodies can decrease the autoimmune activity involved in MG. However, it can also lower some antibodies that contribute to normal immune protection. [3,5]

Infection and vaccination considerations can therefore differ from those associated with broad immune suppression.

For a broader explanation of treatment approaches, see mama health’s guide to treatments used for myasthenia gravis.

Does every MG treatment make you immunocompromised?

No. Not every MG treatment suppresses or weakens immune defences.

Some treatments focus on improving nerve-to-muscle signalling without suppressing the immune system.

Others broadly reduce immune activity.

Newer approaches may target a particular cell type, antibody pathway or part of the immune system.

This is why it can be misleading to place every MG treatment on a simple scale from “mildly immunosuppressive” to “strongly immunosuppressive.”

The type of immune effect matters as well as its strength.

Someone receiving broad immune suppression may face different infection considerations from someone receiving treatment that affects one specific immune defence pathway.

Can infections make myasthenia gravis worse?

Yes. Infections are a recognised trigger for worsening MG symptoms.

Infection places additional stress on the body and can be associated with increased muscle weakness in people living with MG. [1,2]

This means infection can matter in two different ways.

First, some immune-modifying treatments can make the body more susceptible to certain infections.

Second, the infection itself can contribute to worsening MG symptoms.

During an infection, some people may notice greater weakness, fatigue, difficulty speaking or changes in swallowing or breathing.

Severe weakness affecting breathing or swallowing can become an emergency.

For more information about recognising changes in MG, read mama health’s guide to MG symptoms and myasthenic crisis.

Can treatments for infections affect myasthenia gravis?

Yes. Some treatments used for infections can worsen MG in certain people.

This does not mean that every treatment for an infection is unsuitable for someone with MG.

However, some types of prescription treatment have been associated with worsening muscle weakness or interference with neuromuscular transmission. [6]

This makes communication particularly important when treatment for an infection is needed.

It can be useful to tell any healthcare professional involved in prescribing that you live with MG and to provide an up-to-date list of your current treatments.

Some people also choose to carry an MG alert card or relevant information from their specialist team.

For more detail, see mama health’s guide to treatments that may need extra caution with MG.

Do vaccines matter when MG treatment affects the immune system?

Yes. Vaccination can be particularly important when MG treatment changes immune function, but the appropriate vaccine and timing depend on the treatment involved.

Immune-suppressing or immune-targeting treatments may affect:

• which vaccines are appropriate;
• when vaccination can take place;
• how strongly the immune system responds to vaccination;
• whether protection against a specific infection is especially important.

Some types of vaccines may not be suitable during significant immune suppression.

Certain targeted MG treatments also require particular infection-prevention measures because of the immune pathway they affect. [3,4]

Recommendations can change over time and may differ according to age, treatment type and individual health circumstances.

A healthcare professional can explain which vaccination recommendations apply to a particular situation.

What do people living with MG share about infection risk?

Experiences shared through mama health show that questions about immunity can affect everyday decisions, from social contact to conversations with healthcare professionals.

People living with MG describe becoming more aware of infection risk when their treatment affects the immune system. For some, the concern is less about MG itself and more about understanding how their treatment changes their susceptibility to infections.

A recurring experience is that infections can coincide with periods of greater weakness or fatigue. This can make an otherwise familiar infection feel more complicated when someone is also managing MG.

People also describe thinking more carefully about exposure to respiratory infections. This can include avoiding close contact with someone who is unwell, being more cautious in crowded indoor spaces or adapting plans during periods when infections are circulating widely.

Vaccination is another topic that comes up in shared experiences. People describe wanting to understand which vaccines are appropriate for them and how vaccination may fit around immune-modifying treatment.

Another common challenge is communicating important information to different healthcare professionals. People living with MG describe having to explain their condition, current treatment and relevant precautions when speaking with primary care professionals, pharmacists, dentists or emergency healthcare teams.

Some find it helpful to keep an up-to-date treatment list, an MG alert card or other information about their condition available for healthcare visits.

Treatment decisions can also involve competing concerns. People may worry about the infection risks associated with immune-modifying treatment while also considering how uncontrolled MG affects strength, independence and everyday activities.

These shared experiences do not show how common a particular issue is or predict what will happen to an individual. They add another layer of context by showing the practical questions that can arise alongside clinical information.

Questions people living with MG often reflect on include:

• Does my treatment affect my immune system?
• Do I need to take extra precautions around infections?
• Could being unwell affect my MG symptoms?
• What information should I share with other healthcare professionals?
• How do other people with MG approach vaccination, travel or crowded places?

How can shared experiences help when living with MG?

Hearing how other people describe life with MG can help you identify questions and experiences you may want to explore further.

mama health brings together experiences shared by people living with chronic conditions, including MG.

These experiences can provide context around everyday topics that may not always be covered in detail during a healthcare appointment, such as navigating work, social situations, infections, uncertainty and conversations with different healthcare professionals.

They can also help people find words for experiences they recognise in their own lives and prepare questions they may want to discuss with a healthcare professional.

Shared experiences are not medical advice. They cannot determine how MG or a treatment will affect an individual person.

How can people with MG approach everyday infection risk?

Everyday precautions should reflect individual treatment and health factors rather than the MG diagnosis alone.

People receiving immune-suppressing or immune-targeting treatment may receive specific advice about reducing infection risk.

General infection-prevention measures can include:

• regular hand hygiene;
• avoiding close contact with people who are actively unwell;
• keeping recommended vaccinations up to date;
• discussing travel vaccination in advance;
• keeping an up-to-date treatment list;
• making healthcare professionals aware of MG and current treatment.

Some people choose additional precautions in crowded indoor environments or during periods when respiratory infections are widespread.

These decisions can depend on individual circumstances.

Someone using treatment that does not affect immunity may have very different considerations from someone receiving treatment that substantially changes immune function.

Having MG therefore does not automatically mean someone needs to avoid work, travel, social contact or time with family and friends.

What information can be useful to keep available?

Keeping clear information about MG and current treatment can make conversations with healthcare professionals easier.

Useful information may include:

• an up-to-date treatment list;
• known treatment precautions;
• an MG alert card;
• relevant vaccination information;
• details of the specialist team involved in MG care.

This information can be particularly useful when seeing a healthcare professional who does not regularly work with MG.

mama health can also support people in reflecting on their experiences and organising questions they may want to discuss at a future healthcare visit.

What questions could you discuss with a healthcare professional?

Understanding how your own treatment affects immunity is more useful than relying on the general label “immunocompromised.”

Questions you could consider discussing include:

• Does my MG treatment suppress or modify my immune system?
• How significant is that effect in my situation?
• Does my treatment change which vaccines are appropriate for me?
• Are there particular infections I need to be more aware of?
• What could I do if I develop an infection?
• Are there treatments for infections that require extra caution with MG?
• Which changes in breathing, swallowing or muscle strength require urgent assessment?
• Would carrying an MG alert card or treatment summary be useful?

These questions are examples for discussion rather than personalised medical recommendations.

When can worsening MG require urgent medical attention?

Rapid or severe worsening of breathing or swallowing can indicate a serious MG complication and requires urgent medical assessment.

MG can affect the muscles involved in breathing and swallowing.

Severe weakness in these muscles can become life-threatening and may require hospital treatment. Infection is one recognised trigger for serious worsening of MG. [1,2]

A sudden or substantial change in breathing or swallowing should therefore be treated as an urgent medical concern.

So, are people with myasthenia gravis immunocompromised?

Myasthenia gravis does not automatically make someone immunocompromised; the answer often depends on the treatment they receive.

MG is an autoimmune condition. This means the immune response is misdirected rather than simply weak.

Some MG treatments do not suppress immunity.

Other treatments reduce immune activity more broadly, while newer approaches may alter a specific immune pathway.

The practical question is therefore not only:

“Does MG make me immunocompromised?”

It is also:

“How does my particular treatment affect my immune system, and what does that mean for me?”

Understanding that distinction can make it easier to discuss infection prevention, vaccination and everyday precautions with a healthcare professional.

‍
This content is informational and not a medical device.

mama health offers information and support and does not replace a doctor.

1. NHS. Myasthenia gravis. Information on MG, symptom worsening, infections and emergency complications.
2. Association of British Neurologists. Autoimmune Myasthenia Gravis Management Guidelines. UK specialist guidance on MG and its management.
3. International Consensus Guidance for Management of Myasthenia Gravis. Neurology. Consensus guidance covering conventional and targeted immune approaches used in MG.
4. European Medicines Agency. Regulatory and safety information on complement-targeting therapies used in generalised MG.
5. European Medicines Agency. Regulatory and safety information on therapies that reduce circulating antibodies in generalised MG.
6. Myasthenia Gravis Foundation of America. Cautionary Drugs. Information about types of treatment that may worsen MG.